Elacridar
A potent inhibitor of multidrug resistance (MDR) that fully reverses multidrug resistance CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine with IC50 of 0.02 uM; effectively competes with [3H]azidopine for binding P-glycoprotein; restores sensitivity of the tumor to a single dose of doxorubicin in mice; orally bioavailable.Breast Cancer Phase 1 Discontinued (In Vitro) :Elacridar (0.001-1 μM; 2 h) inhibits cell viability of 786-O cells.Elacridar (5 μM; 24 h) affects P-glycoprotein and ABCG2 protein expression levels in MCF-7 and 786-O cell lines.Elacridar (5 μM; 24 h) affects 99mTc-MIBI intracellular accumulation in MCF-7 and 786-O cells. (In Vivo) :Elacridar (100 mg/kg; i.p. once) shows different distribution in brain and plasma.
Product Specifications
CAS Number
143664-11-3
Product Name Alternative
GF-120918 | GW-0918 | GG-918
Purity
>98% (HPLC)
Solubility
10 mM in DMSO
Smiles
COC1=CC=CC2=C1NC3=C (C2=O) C=CC=C3C (=O) NC4=CC=C (C=C4) CCN5CCC6=CC (=C (C=C6C5) OC) OC
Molecular Formula
C34H33N3O5
Molecular Weight
563.6429
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
4-Acridinecarboxamide, N-[4-[2- (3,4-dihydro-6,7-dimethoxy-2 (1H) -isoquinolinyl) ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-
Available Sizes
Explore Other Products
Browse additional items from our catalog
